Cite
HARVARD Citation
Krueger, J. et al. (2016). Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Advances in therapy. 33 (7), pp. 1231-1245. [Online].